CD8A and neoplasm: Bulk and single-cell RNA profiles of CD8+ TILs revealed that combination of Tim-3 and PD-1 blockade expanded the subset of PD-1-CD8+ T cells in the TME, and shift CD8+ T cells from naive-like to Teff or TM, which promoted durable antitumor immune responses and positively correlated with the prognosis of tumor patients (41).